GlassScriptPhysician profile
Amanda Doubrava
NPI 1487362117
$2,744.96
in general payments reported to CMS, 2019-2025
24 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $747 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.91 | 2024-2025 | |
| Pfizer INC. | $483.88 | 2024-2025 | |
| Eisai INC. | $250.51 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $225.22 | 2024-2025 | Nuplazid |
| Celgene Corporation | $182.77 | 2025 | Zeposia |
| Ucb, INC. | $150.28 | 2024-2025 | Rystiggo, Zilbrysq |
| Lilly USA, LLC | $143.91 | 2024-2025 | Kisunla, Reyvow, Emgality |
| Microtransponder, INC. | $97.15 | 2025 | |
| Genentech USA, INC. | $76.21 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Neurocrine Biosciences, INC. | $71.02 | 2025 | |
| Argenx US, INC. | $65.13 | 2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $52.98 | 2025 | Valtoco |
| Janssen Biotech, INC. | $49.52 | 2025 | |
| Axsome Therapeutics, INC. | $31.96 | 2025 | Symbravo |
| Mallinckrodt Hospital Products INC. | $31.70 | 2025 | Acthar |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $27.16 | 2025 | Ponvory |
| Mdd US Operations, LLC | $23.17 | 2024 | Gocovri |
| Kyowa Kirin, INC. | $22.67 | 2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $19.81 | 2025 | Crexont |
| Grifols USA, LLC | $18.89 | 2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $17.74 | 2025 | Radicava |
| Lundbeck LLC | $17.15 | 2024 | Vyepti |
| Globus Medical, INC. | $14.75 | 2025 | Senza |
| Emd Serono, INC. | $13.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Doubrava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.